Needham starts coverage on Evommune; shares gain
26/08/2026 17:32
BUZZ-Needham starts coverage on Evommune; shares gain ** Shares of drug developer Evommune EVMN.N rise 1.7% to $14.02
** Needham starts coverage on EVMN with "buy" rating and $28 PT
** Says rating based on co's "promising I&I pipeline, notably EVO301, an IL-18 inhibitor fusion protein, that has demonstrated proof-of-concept efficacy on par (or better) vs. current biologics for atopic dermatitis (AD)"
** Adds "upcoming Sept readout of the ph 2b trial in AD could generate significant shareholder value"
** EVMN has lost over 18% since its debut in November last year
(Reporting by Sudeshna Ghoshal in Bengaluru)